Cas:39930-11-5 Phenyl-pyridin-2-ylmethyl-amine manufacturer & supplier

Chemical Name:Phenyl-pyridin-2-ylmethyl-amine

CAS.NO:39930-11-5

Synonyms:2-Pyridinemethanamine, α-phenyl-;2-aziridin-1-yl-1-phenyl-ethanol;1-phenyl-2-pyridin-2-yl-ethylamine;Phenyl-pyridin-2-ylmethyl-amine;1-Phenyl-1-(2-pyridinyl)methanamine;1-phenyl-1-(pyridin-2-yl)methanamine;1-phenyl-1-pyridin-2-ylmethanamine

Molecular Formula:C₁₂H₁₂N₂

Molecular Weight:184.237

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:312.2±27.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.603

PSA:38.91000

Exact Mass:184.100052

LogP:1.30

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Pyridinemethanamine, α-phenyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-phenyl-1-pyridin-2-ylmethanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenyl-pyridin-2-ylmethyl-amine Use and application,1-phenyl-1-(pyridin-2-yl)methanamine technical grade,usp/ep/jp grade.

Related News: The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. Phenyl-pyridin-2-ylmethyl-amine manufacturer ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety. Phenyl-pyridin-2-ylmethyl-amine supplier The South Korean government is banning entry to all foreign nationals who visited China’s Hubei province in the past 14 days. Phenyl-pyridin-2-ylmethyl-amine vendor f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. Phenyl-pyridin-2-ylmethyl-amine factory ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment��s chemistry, manufacturing and controls process, but not its safety.